August 21, 2007 - Omicia Inc., a privately held company specializing in personalized genetic signatures for early detection of disease risk, has been awarded its fourth NIH grant, a $182,732 Small Business Technology Transfer (STTR) Phase I grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health, aiming to identify genes whose variants increase the risk of developing cardiovascular disease.
This industry/academia collaboration is between Omicia and Johns Hopkins University (JHU).
